{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-016245","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.401817+00:00","generated_at":"2026-06-16T05:11:12.969954+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TransMedics Q1 revenue $41.6M (+162% YoY); raises FY23 guidance to $160-170M","bullets":["Q1 2023 revenue $41.6M (+162% YoY from $15.9M) driven by NOP adoption and OCS Liver/Heart sales.","Gross margin 69% vs 76% in Q1 2022 and 66% in Q4 2022.","Net loss improved to $2.6M from $10.6M in Q1 2022.","Operating expenses $30.9M (incl. $3.9M stock comp) vs $21.5M (incl. $2.3M) in prior year.","FY2023 revenue guidance raised to $160-170M (71-82% growth) from prior $138-145M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-016245","json":"https://secwatch.observer/filing/0000950170-23-016245.json","markdown":"https://secwatch.observer/filing/0000950170-23-016245.md","text":"https://secwatch.observer/filing/0000950170-23-016245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023016245/0000950170-23-016245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023016245/tmdx-20230501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:11:12.969954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14b565003a3267ecf5c39193110d5319bd8852a6","claim":"TransMedics Group, Inc. reported the quarter ended March 31, 2023 results: revenue $41.6 million, net income $2.6 million, EPS $(0.34) per diluted share. Guidance raised.","evidence_excerpt":"TransMedics Reports First Quarter 2023 Financial Results Andover, Mass. – May 1, 2023 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023. Recent Highlights ▪ Net revenue of $41.6 million in the first quarter of 2023, a 162% increase compared to the first quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023016245/0000950170-23-016245-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$41.6 million"},{"label":"Net income","value":"$2.6 million"},{"label":"EPS","value":"$(0.34) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}